Title: Clinical study on Diclofenac Sodium Sustained Release Capsules combined with Sulfasalazine in treatment of rheumatoid arthritis
Abstract: Objective To explore the clinical effect of Diclofenac Sodium Sustained Release Capsules combined with Sulfasalazine in treatment of rheumatoid arthritis. Methods Patients(114 cases) with rheumatoid arthritis in Zhangjiafang Hospital of Traditional Chinese Medicine from October 2011 to in October 2014 were randomly divided into control and treatment groups, and each group had 57 cases. The patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, with initial dosage of 4 tablets/time, three times daily. If the patient had no obvious discomfort, the dosage could be gradually increased to 6 tablets/time, three times daily. If symptoms could be improved, the dosage was reduced, 2 tablets/time, three times daily. The patients in the treatment group were po administered with Diclofenac Sodium Sustained Release Capsules on the basis of the control group, 1 grain/time, twice daily. The patients in two groups were treated for 6 months. After treatment, the efficacy was evaluated, and the improvement degree of signs and symptoms, joints functional grading and X-ray classification in two groups were compared. The changes of ESR, CRP, Ig A, Ig G, and Ig M in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 75.44% and 92.98%, respectively, and there were differences between two groups(P 0.05). After treatment, scores of joint pain, joint tenderness, joint swelling, and activity obstacle were significantly lowered, and morning stiffness time was significantly shortened, and the difference was statistically significant in the same group(P 0.05). These observational indexes in treatment group were better than those in control group, with significant difference between two groups(P 0.05). After treatment, ESR, CRP, Ig A, Ig G, and Ig M in two groups were significantly decreased, and the difference was statistically significant in the same group(P 0.05). These observational indexes in treatment group were better than those in control group, with significant difference between two groups(P 0.05). After treatment, joints functional grading and X-ray classification in two groups had significantly improved, and the improvement degree of the treatment group was obviously better than that in the control group, with significant difference between two groups(P 0.05). Conclusion Diclofenac Sodium Sustained Release Capsules combined with Sulfasalazine has clinical curative effect in treatment of rheumatoid arthritis, and can significantly improve the symptoms and signs, and can adjust the immunity of patients, which has a certain clinical application value.
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot